Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer

Simple Summary Pancreatic cancer (PC) is known to be difficult to treat, even with standard-of-care chemotherapies. One emerging option for treating PC involves high-dose radiation therapy as a means to help control the growth and even destroy cancer cells. However, the pancreas is surrounded by many gastrointestinal organs and blood vessels; therefore, the implantation of a gold fiducial marker can help precisely target the pancreatic tumor. Our aim was to investigate whether implantation of fiducial markers through endoscopic ultrasound guidance is safe and feasible and to also document the radiation characteristics of this emerging high-dose radiation treatment option. Abstract Accurate delivery of stereotactic body radiotherapy (SBRT) to pancreatic tumors relies on successful EUS-guided placement of fiducial markers. The aim of this study is to report the technical feasibility and safety of EUS-guided fiducial placement and to evaluate the characteristics and technical benefit of SBRT in a cohort of patients with pancreatic cancer (PC). A retrospective chart review was performed for all (n = 82) PC patients referred for EUS-guided fiducial placement by a single endosonographer at a tertiary cancer center. Data regarding EUS-related technical details, SBRT characteristics, adverse events, and continuous visibility of fiducials were recorded and analyzed. Most patients included in the study had either locally advanced disease (32 patients, 39%) or borderline resectable disease (29 patients, 35%). Eighty-two PC patients underwent the placement of 230 fiducial markers under EUS guidance. The technical success rate of the fiducial placement was 98%. No immediate EUS-related adverse events were reported. The average time to the simulation CT after fiducial placement was 3.1 days. Of the 216 fiducial markers used for the SBRT delivery, 202 fiducial markers were visible on both the simulation CT and the cone beam CT scan. A median dose of 40cGY was given to all the patients in five fractions. Of these, 41% of the patients reported no SBRT-related toxicities during the follow-up. Fatigue and nausea were the most reported SBRT-related toxicities, which were seen in 35% of the patients post-SBRT. Our results demonstrate that EUS-guided fiducial placement is safe and effective in target volume delineation, facilitating SBRT delivery in PC patients. Further clinical trials are needed to determine the SBRT-related survival benefits in patients with pancreatic cancer.

[1]  R. Brand,et al.  Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk assessment, Early Detection, and Prevention. , 2023, Gastroenterology.

[2]  E. Shin,et al.  Endoscopic Ultrasound–Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Pancreatic Malignancy , 2021, Clinical endoscopy.

[3]  L. Moretti,et al.  EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score , 2021, Endoscopy International Open.

[4]  E. Holliday,et al.  Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer , 2020, Advances in radiation oncology.

[5]  D. Forcione,et al.  Endoscopic ultrasound-guided fiducial marker placement in pancreatic cancer: A systematic review and meta-analysis , 2020, World journal of gastrointestinal endoscopy.

[6]  A. Zwinderman,et al.  Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jordan M Slagowski,et al.  Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image-Guided Stereotactic Body Radiation Therapy in the Abdomen. , 2020, Practical radiation oncology.

[8]  T. Berzin,et al.  EUS-guided fiducial placement for pancreatobiliary malignancies: safety, infection risk, and use of peri-procedural antibiotics , 2020, Endoscopy International Open.

[9]  Mihir S. Wagh,et al.  Endoscopic Ultrasound Placement of Preloaded Fiducial Markers Shortens Procedure Time Compared to Back-Loaded Markers. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  S. Prados,et al.  Endoscopic ultrasound-guided fiducial placement in pancreatic tumors: safety and technical feasibility. , 2019, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[11]  M. Tempero.  NCCN Guidelines Updates: Pancreatic Cancer. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  C. Taniguchi,et al.  EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis. , 2019, Gastrointestinal endoscopy.

[13]  Jeffrey W. Clark,et al.  Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial , 2018, JAMA oncology.

[14]  D. Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[15]  S. Hoffe,et al.  Endoscopic ultrasound-guided fiducial marker placement for image-guided radiation therapy without fluoroscopy: safety and technical feasibility , 2016, Endoscopy International Open.

[16]  Albert C. Koong,et al.  Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma , 2014, Cancer.

[17]  B. Chang,et al.  Locally advanced unresectable pancreatic cancer. , 2014, JOP : Journal of the pancreas.

[18]  M. Katz,et al.  Management of borderline resectable pancreatic cancer. , 2014, Seminars in radiation oncology.

[19]  Myung-Hwan Kim,et al.  Fiducial Placement for Stereotactic Body Radiation Therapy under Only Endoscopic Ultrasonography Guidance in Pancreatic and Hepatic Malignancy: Practical Feasibility and Safety , 2013, Gut and liver.

[20]  Vikesh K. Singh,et al.  Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. , 2012, Gastrointestinal endoscopy.

[21]  T. Desser,et al.  Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.

[22]  K. Goodman,et al.  EUS-guided fiducial placement for image-guided radiation therapy in GI malignancies by using a 22-gauge needle (with videos). , 2010, Gastrointestinal endoscopy.

[23]  Herbert J Zeh,et al.  EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. , 2010, Gastrointestinal endoscopy.

[24]  Walter G. Park,et al.  EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. , 2010, Gastrointestinal endoscopy.

[25]  Albert Koong,et al.  Safety and efficacy of percutaneous fiducial marker implantation for image-guided radiation therapy. , 2009, Journal of vascular and interventional radiology : JVIR.

[26]  Lei Xing,et al.  Stereotactic body radiation therapy in multiple organ sites. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Gagnon,et al.  EUS-guided fiducial placement for CyberKnife radiotherapy of mediastinal and abdominal malignancies. , 2006, Gastrointestinal endoscopy.

[28]  Quynh-Thu Le,et al.  Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. , 2005, International journal of radiation oncology, biology, physics.

[29]  J. Roeske,et al.  Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. , 2004, International journal of radiation oncology, biology, physics.

[30]  R. Nelson,et al.  Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. , 2003, Gastrointestinal endoscopy.

[31]  A. Khorana,et al.  Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. , 2019, Practical radiation oncology.

[32]  S. Russo,et al.  Gastrointestinal Malignancies , 2018, Practical Guides in Radiation Oncology.

[33]  Vladimir Feygelman,et al.  Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy. , 2013, Practical radiation oncology.